New hope for newborns: safer seizure treatment for Brain-Injured babies
NCT ID NCT07284498
First seen Jan 11, 2026 · Last updated Jun 17, 2026 · Updated 28 times
Summary
This study tests two medicines, phenobarbital and levetiracetam, to see which works better and is safer for stopping seizures in newborns with moderate to severe brain injury from lack of oxygen (HIE). About 66 babies will receive one of the drugs, and doctors will check if seizures stop within 20-40 minutes and stay away for 24-48 hours. The goal is to find a treatment that controls seizures quickly without needing extra medicines.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEONATAL SEIZURES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Al Galaa Teaching Hospital
Cairo, Egypt
-
University Children's Hospital, Mansoura University
Al Mansurah, Egypt
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.